YI

• Macroeconomic challenges: The healthcare sector faced headwinds from macroeconomic pressures and healthcare reforms, with per capita healthcare expenditure growth slowing. Downstream pharmacies had pressure from reforms and aggressive pre-pandemic expansion leading to stagnant sales.
• Digital transformation: Essential for survival and growth, with integration of leading technologies across operations, from sales to inventory optimization. AI and digitization are key to enhancing efficiency and customer engagement.
• Financial highlights: Achieved first ever operational profitability and positive operating cash flow in 2024. Operating expenses reduced significantly, with operating expense ratio improving to record lows.
• Technology advancements: Integrated AI in demand analysis, supply chain optimization, and market responsiveness. Expanded product portfolio via AI-powered catalogs, improved forecasting accuracy, and reduced stock-out rates.
• Supply chain improvements: Initiated and expanded the Kunpeng Network, adding fulfillment centers, expanding delivery coverage, and reducing order damage rates and delivery times.
• Industry recognitions: Recognized as a valuable healthcare company, top private enterprise in Chongqing, and outstanding case of a productive internet service platform in Shanghai.

• Continue to build scale and efficiency with AI support in 2025.
• Expect sustainable profitability going forward, driven by robust technology capabilities and continued focus on operational efficiency.

In Q4 2024, total net revenues were RMB3.8 billion, with gross segment profit of RMB202.5 million. For the full year 2024, net revenues were RMB14.4 billion and gross segment profit was RMB829.2 million. Operating expenses as a percentage of revenues improved in Q4 to 5.5% and for the full year 2024 to 5.7%. Total operating expenses for Q4 2024 decreased 50.1% to RMB209.8 million, and for full year 2024, they decreased 31% to RMB827.1 million.

• Arbitration outcome regarding redemption requests from investors: An arbitration ruled in favor of an investment seeking redemption, requiring repurchase, but not expected to impact PRC entities' business operations. Ongoing discussions with investors to finalize revised repayment schedule.

Q: How did the unfavorable macroeconomic environment affect the company’s performance in Q4 2024 and full year 2024?

A: Despite tough macro conditions, the company achieved operating profits and positive cash flow, slashing operating expenditure and improving efficiency. Even with revenue decreases, they maintained profitability through strategic initiatives.

Q: What are the main factors driving gross margin improvement?

A: Outsourcing low-margin products to partners, focusing on higher-margin products including private labels, using decentralized inventory models, and AI-assisted assortment management.

Q: Any further expense control actions expected in 2025?

A: Continue to utilize AI and internet technologies for structural cost optimization, already ingrained in the company's DNA.

Q: Talk about technology advancement, especially AI applications.

A: Integrated AI in price intelligence, product selection, supply chain optimization, and customer service. Plan to develop AI agents and integrate AI as a core engine for end-to-end technology integration.

Q: Plans for AI investment budgeting?

A: AI is a big part of the strategy, with plans to develop various AI agents and integrate AI as a core engine driving multiple aspects of the business.

Q: Plans to expand partnerships with pharmaceutical companies and market outlook?

A: Will expand cooperation with upstream and downstream partners to enable drug entry into retail terminals and better promotion via AI-powered platforms. Expect government to introduce policies encouraging innovation, leveraging the company's AI and digitization advantages.